Precigen has the same combination that made Xeris work: a fast-growing product and a pipeline the market isn’t pricing in.
Xeris Biopharma reported Q3 2026 revenue of US$107.23 million and net income of US$11.29 million, and then raised full year 2026 revenue guidance to between US$395 million and US$405 million after strong Recorlev demand. The business remained in a loss position over the first nine months of 2026 despite higher sales, which keeps execution, spending discipline, and product concentration in focus for anyone tracking the sustainability of this upswing. This section now looks at how Xeris...
Xeris Biopharma Holdings (NasdaqGS:XERS) has appointed Menassie M. Taddese to its Board of Directors. Taddese brings nearly 30 years of global biopharma experience, including senior roles at Viatris and Pfizer. His background spans commercial operations, business transformation, and financial oversight across multiple international markets. The new Board appointment of Menassie M. Taddese is only part of Xeris Biopharma's wider investment story. Our analysis turns up 1 warning sign for Xeris...
Xeris Pharmaceuticals (XERS) stock hits a 52-week high as the company posts better than expected financials and raises its outlook. Read more here.
Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.
Detailed price information for Xeris Pharmaceuticals Inc (XERS-Q) from The Globe and Mail including charting and trades.
CHICAGO, September 09, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive clinical development strategy, including Cornerstone, its Phase 3 registrational study design, as well as the commercial opportunity for XP-8121, its investigational once-weekly s
This is the newest page. Registered accounts read further back.